Biocon has signed an out-licensing agreement with Ajanta Pharma, a specialty pharmaceutical formulations company, to market its vertically integrated drug product, Semaglutide, used to improve glycemic control in adults with type-2 diabetes.
Under the terms of this agreement, Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
